Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
2000 1
2002 2
2003 1
2005 1
2007 1
2008 1
2010 1
2012 1
2014 2
2015 2
2016 2
2018 4
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

21 results
Results by year
Filters applied: . Clear all
Page 1
[Oncolytic Properties of a Mumps Virus Vaccine Strain in Human Melanoma Cell Lines].
Ammour YI, Ryabaya OO, Milovanova AV, Sidorov AV, Shohin IE, Zverev VV, Nasedkina TV. Ammour YI, et al. Mol Biol (Mosk). 2018 Jul-Aug;52(4):659-666. doi: 10.1134/S002689841804002X. Mol Biol (Mosk). 2018. PMID: 30113031 Free article. Russian.
The oncolytic potential of the attenuated mumps virus (MV) vaccine strain Leningrad-3 (L-3) was evaluated in a panel of four human metastatic melanoma cell lines. ...Based on the results, MV L-3 was assumed to be a promising oncolytic agent for human melanoma …
The oncolytic potential of the attenuated mumps virus (MV) vaccine strain Leningrad-3 (L-3) was evaluated in a panel of four h …
[Oncolytic Paramyxoviruses: Mechanism of Action, Preclinical and Clinical Studies].
Matveeva OV, Kochneva GV, Zainutdinov SS, Ilyinskaya GV, Chumakov PM. Matveeva OV, et al. Mol Biol (Mosk). 2018 May-Jun;52(3):360-379. doi: 10.7868/S0026898418030023. Mol Biol (Mosk). 2018. PMID: 29989571 Free article. Review. Russian.
Preclinical studies demonstrate that a broad spectrum of human and animal malignant cells can be killed by oncolytic paramyxoviruses, which includes cells of ecto-, endo- and mesodermal origin. ...Thanks to cytoplasmic replication, paramyxoviruses do not integrate the host …
Preclinical studies demonstrate that a broad spectrum of human and animal malignant cells can be killed by oncolytic paramyxoviruses, …
Recombinant mumps virus as a cancer therapeutic agent.
Ammayappan A, Russell SJ, Federspiel MJ. Ammayappan A, et al. Mol Ther Oncolytics. 2016 Aug 10;3:16019. doi: 10.1038/mto.2016.19. eCollection 2016. Mol Ther Oncolytics. 2016. PMID: 27556105 Free PMC article.
Mumps virus belongs to the family of Paramyxoviridae and has the potential to be an oncolytic agent. ...Recent success stories of oncolytic clinical trials prompted us to resurrect the mumps virus and to explore its potential for cancer treatment. ...
Mumps virus belongs to the family of Paramyxoviridae and has the potential to be an oncolytic agent. ...Recent success stories …
Combination of Vaccine-Strain Measles and Mumps Viruses Enhances Oncolytic Activity against Human Solid Malignancies.
Son HA, Zhang L, Cuong BK, Van Tong H, Cuong LD, Hang NT, Nhung HTM, Yamamoto N, Toan NL. Son HA, et al. Cancer Invest. 2018 Feb 7;36(2):106-117. doi: 10.1080/07357907.2018.1434539. Epub 2018 Feb 27. Cancer Invest. 2018. PMID: 29485292
Oncolytic measles and mumps viruses (MeV, MuV) have a potential for anti-cancer treatment. ...
Oncolytic measles and mumps viruses (MeV, MuV) have a potential for anti-cancer treatment. ...
Macrophage response to oncolytic paramyxoviruses potentiates virus-mediated tumor cell killing.
Tan DQ, Zhang L, Ohba K, Ye M, Ichiyama K, Yamamoto N. Tan DQ, et al. Eur J Immunol. 2016 Apr;46(4):919-28. doi: 10.1002/eji.201545915. Epub 2016 Feb 3. Eur J Immunol. 2016. PMID: 26763072 Free article.
Tumor-associated macrophages (TAMs) are known to regulate tumor response to many anti-cancer therapies, including oncolytic virotherapy. Oncolytic virotherapy employing oncolytic paramyxoviruses, such as attenuated measles (MeV) and mumps (MuV) viruses …
Tumor-associated macrophages (TAMs) are known to regulate tumor response to many anti-cancer therapies, including oncolytic virothera …
Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer.
Myers R, Greiner S, Harvey M, Soeffker D, Frenzke M, Abraham K, Shaw A, Rozenblatt S, Federspiel MJ, Russell SJ, Peng KW. Myers R, et al. Cancer Gene Ther. 2005 Jul;12(7):593-9. doi: 10.1038/sj.cgt.7700823. Cancer Gene Ther. 2005. PMID: 15746945
Oncolytic viruses are promising cytoreductive agents for cancer treatment but extensive human testing will be required before they are made commercially available. Here, we investigated the oncolytic potential of two commercially available live attenuated vaccines, …
Oncolytic viruses are promising cytoreductive agents for cancer treatment but extensive human testing will be required before they ar …
Newcastle disease virus (NDV): brief history of its oncolytic strains.
Sinkovics JG, Horvath JC. Sinkovics JG, et al. J Clin Virol. 2000 Feb;16(1):1-15. doi: 10.1016/s1386-6532(99)00072-4. J Clin Virol. 2000. PMID: 10680736 Review.
BACKGROUND: While genetically engineered viruses are now being tested for the virus therapy of human cancers, some naturally occurring viruses display unmatched oncolytic activity. Newcastle disease virus (NDV) excels as an oncolytic agent. OBJECTIVES: As its virule …
BACKGROUND: While genetically engineered viruses are now being tested for the virus therapy of human cancers, some naturally occurring virus …
[Progress in Newcastle disease virus against tumor].
Wang B, Song L, Ma D, Dong Y, Wang X. Wang B, et al. Sheng Wu Gong Cheng Xue Bao. 2018 Sep 25;34(9):1432-1441. doi: 10.13345/j.cjb.180153. Sheng Wu Gong Cheng Xue Bao. 2018. PMID: 30255677 Free article. Review. Chinese.
Newcastle disease virus is paramyxoviridae, Avian mumps virus genus type I, and infects more than 250 species of birds, causing huge losses on poultry farming worldwide. Numerous experiments have demonstrated that Newcastle disease virus has oncolytic activity on tu …
Newcastle disease virus is paramyxoviridae, Avian mumps virus genus type I, and infects more than 250 species of birds, causing huge …
Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions.
Liu TC, Kirn D. Liu TC, et al. Cancer Res. 2007 Jan 15;67(2):429-32. doi: 10.1158/0008-5472.CAN-06-2871. Cancer Res. 2007. PMID: 17234747 Review.
Oncolytic viruses that can destroy cancer cells have been engineered in a variety of ways with the aim of improving their selectivity and efficacy. Here, we review data from clinical investigations of these virotherapeutic agents, specifically those that have shown systemi …
Oncolytic viruses that can destroy cancer cells have been engineered in a variety of ways with the aim of improving their selectivity …
RNA viruses as virotherapy agents.
Russell SJ. Russell SJ. Cancer Gene Ther. 2002 Dec;9(12):961-6. doi: 10.1038/sj.cgt.7700535. Cancer Gene Ther. 2002. PMID: 12522435 Review.
RNA viruses are rapidly emerging as extraordinarily promising agents for oncolytic virotherapy. Integral to the lifecycles of all RNA viruses is the formation of double-stranded RNA, which activates a spectrum of cellular defense mechanisms including the activation of PKR …
RNA viruses are rapidly emerging as extraordinarily promising agents for oncolytic virotherapy. Integral to the lifecycles of all RNA …
21 results